19420-41-8

Basic information

• Product Name: 3-(2-Propynyl)benzoxazol-2(3H)-one
• Synonyms: 3-(2-Propynyl)benzoxazol-2(3H)-one
• CAS NO: 19420-41-8
• Molecular Formula: C10H7NO2
• Molecular Weight: 0
• Mol File: 19420-41-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 279.5°C at 760 mmHg
• Flash Point: 122.8°C
• Appearance: /
• Density: 1.283g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.601
• CAS DataBase Reference: 3-(2-Propynyl)benzoxazol-2(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-Propynyl)benzoxazol-2(3H)-one(19420-41-8)
• EPA Substance Registry System: 3-(2-Propynyl)benzoxazol-2(3H)-one(19420-41-8)

Safety Data

• Hazardous Substances Data: 19420-41-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H7NO2/c1-2-7-11-8-5-3-4-6-9(8)13-10(11)12/h1,3-6H,7H2

Upstream product

• 106-96-7 propargyl bromide 
• 934-34-9 2-hydroxybenzothiazole 
• 59-49-4 2-Benzoxazolinone 

Relevant articles and documents

Synthesis of novel triazole based benzoxazolinones: Their TNF-α based molecular docking with in-vivo anti-inflammatory, antinociceptive activities and ulcerogenic risk evaluation

A library of novel bis-heterocycles containing benzoxazolinone based 1,2,3-triazoles has been synthesized using click chemistry approach. The compound 3f exhibited potent selective COX-2 inhibition of 59.48% in comparison to standard drug celecoxib (66.36% inhibition). The compound 3i showed significant (p 0.001, 50.95%), TNF-α inhibitory activity as compared to indomethacin (p 0.001, 64.01%). The results of the carrageenan induced hind paw oedema showed that compounds 3a, 3f, 3i, 3o, and 3e exhibited potent anti-inflammatory activity in comparison to Indomethacin. The molecular docking studies revealed that 3i exhibits strong inhibitory effect due to the extra stability of the complex because of an extra π-π bond. The histopathology report showed that none of the compounds caused gastric ulceration.

Benzimidazolidinone derivatives as muscarinic agents

Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.

3-substituted-2-benzoxazolinones.

-